Safety and Immunologic Effect of Low Dose Versus High Dose Vitamin D3 in Multiple Sclerosis

A Pilot Study to Assess the Relative Safety and Immunology Effects of Low Dose Versus High Dose Cholecalciferol Supplementation in Patients With Multiple Sclerosis

The purpose of this study is to determine the safety and the immunologic effects of supplementation with low-dose and high-dose cholecalciferol (vitamin D3) in patients with multiple sclerosis.

Inclusion Criteria:

• Between ages of 18-55 years (inclusive)
• Serum 25(OH) vitamin D levels between 20-50 ng/mL and a candidate for vitamin D supplementation
• Patients with or without immunomodulatory therapy for RRMS
• Diagnosis of multiple sclerosis

Exclusion Criteria:

• Serum 25(OH) vitamin D deficient level < 20 ng/mL
• High dose vitamin D supplementation in the past 3 months
• Pregnancy
• History of tuberculosis, hyperparathyroidism, sarcoidosis or kidney stones
• Baseline serum creatinine above 1.5
• Hypersensitivity to vitamin D preparations
• Milk allergy
• Unable to consent